Back to top
more

DENTSPLY SIRONA Inc. (XRAY)

(Delayed Data from NSDQ)

$51.67 USD

51.67
1,271,316

-1.28 (-2.42%)

Updated Aug 23, 2019 04:00 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.80%
17.93%
9.58%
5.18%
2.03%
10.63%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

B Value | C Growth | B Momentum | B VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Allscripts' (MDRX) Veradigm Collaborates With Komodo Health

Allscripts (MDRX) expects its Veradigm business to drive bookings in 2019.

MDRX ISRG BAX XRAY

Zacks Equity Research

Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline

Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).

ABT TNDM BAX XRAY

Zacks Equity Research

FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk

With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.

ABT BAX MDT XRAY

Zacks Equity Research

Here's Why You Should Add Stryker (SYK) to Your Portfolio

Stryker (SYK) gains from core segments in the second quarter of 2019.

ISRG BAX SYK XRAY

Zacks Equity Research

Here's Why You Should Hold Varian Medical (VAR) Stock Now

Varian (VAR) raises the revenue guidance for fiscal 2019.

VAR BSX BAX XRAY

Zacks Equity Research

Here's Why You Should Snap Up Baxter International (BAX) Now

For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.

ISRG BAX SYK XRAY

Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

XRAY vs. COO: Which Stock Is the Better Value Option?

XRAY COO

Zacks Equity Research

Stock Market News For Aug 5, 2019

Benchmarks closed in the red on Friday to post their worst single-day decline in a month.

GOL FB BA DVA XRAY

Zacks Equity Research

Stock Market News for Aug 02, 2019

Benchmarks closed lower on Thursday after President Trump announced plans to impose additional tariffs on imports from China.

GOL VZ GM AAPL K CAT DE DVA XRAY YUM NKE PVH FDX YETI

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q2 Earnings Beat, Revenues Fall Y/Y

DENTSPLY SIRONA (XRAY) raises guidance for 2019 adjusted EPS.

ISRG BAX SYK XRAY

Zacks Equity Research

Dentsply International (XRAY) Q2 Earnings Top Estimates

Dentsply (XRAY) delivered earnings and revenue surprises of 6.45% and -2.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

XRAY

Zacks Equity Research

Why Earnings Season Could Be Great for Dentsply Sirona (XRAY)

Dentsply Sirona (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

XRAY

Zacks Equity Research

Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?

Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.

DVA BDX XRAY ALNA

Zacks Equity Research

Will Genetic Testing Drive Invitae's (NVTA) Q2 Earnings?

Invitae (NVTA) expects to deliver a strong second quarter, banking on solid performance of its genetic testing business.

NVTA AMED XRAY ABC

Zacks Equity Research

Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.

Zacks Equity Research

Why Dentsply (XRAY) Could Beat Earnings Estimates Again

Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

What's in the Cards for DaVita (DVA) This Earnings Season?

DaVita (DVA) projects operating income within $460-$465 million for the second quarter.

Zacks Equity Research

GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand

GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.

Zacks Equity Research

What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

Better-than-expected performance at Technology & Equipment and growth in emerging markets are likely to aid DENTSPLY SIRONA (XRAY) in Q2 earnings.

Zacks Equity Research

Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View

Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.

TFX HOLX ZBH XRAY

Zacks Equity Research

Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?

In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.

TNDM IDXX HSIC XRAY

Zacks Equity Research

Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View

Omnicell (OMCL) aims at product innovation through R&D.

OMCL TFX HOLX XRAY

Zacks Equity Research

AmerisourceBergen (ABC) Q3 Earnings: What's in the Offing?

Better-than-expected performance at Pharmaceutical Distribution and higher revenues are likely to aid AmerisourceBergen (ABC) in Q3 earnings.

HSIC XRAY ABC ALNA

Zacks Equity Research

Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates

Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.

TFX HOLX SYK XRAY

Zacks Equity Research

Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates

Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.

TFX HOLX MMSI XRAY